Pfizer Inc. (PFE)
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline
Despite recent underperformance, a "Buy" rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength. Management's focus on non-COVID segments and aggressive cost-cutting initiatives are expected to support margins and EPS growth, trending towards the upper end of FY2025 guidance. Impending LOEs for key drugs ( ~$17B peak revenue by 2026-2030) are a concern, but Pfizer is actively investing in its pipeline, especially oncology and vaccines, to offset this.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature, results from competitors such as Instil Bio are promising. We think Instil Bio, through its low valuation, and Pfizer, given its dividend yield, constitute good Buy opportunities to get exposure to the field.
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors.
Pfizer Looks Like A Great Play At Current Valuations
Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, while maintaining solid margins and forward growth expectations. Risks include increased competition in the ATTR-CM market and ongoing technical downtrends, but cost-cutting measures may enhance efficiency.
Pfizer Thinks Bigger With 3SBio Deal
Pfizer Inc. decided to think bigger after the Summit deal in February and that it needs control of a PD-1/VEGF bispecific antibody versus participating with its ADC pipeline. The 3SBio deal allows increased control of its oncology pipeline and much higher financial rewards in the long run, and comes at a relatively low cost. The jury is still out on the PD-1/VEGF bispecific antibody class of drugs, but the data to date make this approach worth exploring, and perhaps even necessary.
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Pfizer (PFE) has announced a new agreement to develop and market a cancer drug currently being developed by Chinese drugmaker 3SBio.
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.
Pfizer signs $6bn licensing deal with China's 3SBio for cancer drug
Pfizer Inc (NYSE:PFE, ETR:PFE) has agreed a licensing deal worth up to $6 billion with Chinese biopharmaceutical group 3SBio to develop and commercialise an experimental cancer treatment. The drug, SSGJ-707, is currently in clinical trials in China for use against lung, colorectal and gynaecological cancers.
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Pfizer's Turnaround Story Is Stronger Than You Think
On April 29, 2025, Pfizer beat consensus EPS estimates for the twelfth consecutive quarter by a wide margin, creating a divergence with its stock price, which continues to move sideways. I was pleasantly surprised by the strong performance of Pfizer's oncology and cardiovascular franchises, as well as the positive effects of its cost-cutting program. So, the Vyndaqel family's sales amounted to about $1.49 billion, increasing by 30.7% year-on-year, despite competition from BridgeBio's Attruby and Alnylam Pharmaceuticals' Amvuttra.
